Excitation of type II anterior caudate neurons by stimulation of dopamine D3 receptors

Brain Research

Volumn 762, Issue 1-2, 1997, Pages 19-28

  Piercey, Montford F ^a   Hyslop, Deborah K ^a   Hoffmann, William E ^a  

^a PFIZER INC   (United States)

Author keywords

Anterior caudate; DA agonist; Parkinson's disease; Pramipexole; Type II neuron

Indexed keywords

5 METHOXY 1 METHYL 2 PROPYLAMINOTETRALIN; AMPHETAMINE; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE 3 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; HALOPERIDOL; PNU 91356A; PRAMIPEXOLE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CAUDATE NUCLEUS; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; NONHUMAN; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA;

8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; AMINOQUINOLINES; ANIMALS; BENZOTHIAZOLES; CAUDATE NUCLEUS; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPHYSIOLOGY; HALOPERIDOL; IMIDAZOLES; NEURONS; QUINPIROLE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; RECEPTORS, SEROTONIN; RECEPTORS, SEROTONIN, 5-HT1; SEROTONIN AGONISTS; TETRAHYDRONAPHTHALENES; THIAZOLES;

EID: 0030792213     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(97)00369-7     Document Type: Article

References (40)

1. 3 subtypes. Brain Res. 649:1994;95-110.
2. Blanchet P.J., Calon F., Martel J.C., Bedard P.J., DiPaolo T., Walters R.R., Piercey M.F. Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D2 agonist (U-91356A) in MPTP monkeys. J. Pharmacol. Exp. Ther. 272:1995;854-859.
3. 2 receptor mRNA. Brain Res. 554:1991;203-219.
4. Bunney B.S., Aghajanian G.K. d-Amphetamine-induced depression of central dopamine neurons: evidence for mediation by both autoreceptors and a striato-nigral feedback pathway. Naunyn-Schmiedeberg's Arch. Pharmacol. 304:1978;255-261.
5. 3-preferring dopamine agonist. Neurosci. Lett. 196:1995;97-100.
6. Civelli O., Bunzow J.R., Grandy K.D. Molecular diversity of the dopamine receptors. Annu. Rev. Pharmacol. Toxicol. 32:1993;281-307.
7. Gerfen C.R. The neostriatal mosaic: multiple levels of compartmental organization. Trends Neurosci. 15:1992;1333139.
8. Goetz C.G., Tanner C.M., Glantz R.H., Klawans H.l. Chronic agonist therapy for Parkinson's disease: a five-year study of BCT and PERG. Neurology. 35:1985;749-751.
9. Goetz C.G., Diederich N.J. Dopaminergic agonists in the treatment of Parkinson's disease. Neurol. Clin. 10:1992;527-540.
10. Haracz J.L., Tscjamz J.T., Greeberg J., Rebec G.V. Amphetamine-induced excitations predominate in single neurons showing motor-related activity. Brain Res. 489:1989;363-368.
11. Hjorth S. On the mode of action of 3-(3-hydroxyphenyl)-N-n-propylpiperidine, 3-PPP, and its enantiomers. Acta Physiol. Scand. S517:1983;1-52.
12. 3-preferring agonist. Neurosci. Abstr. 21:1995;1142.
13. Hornykiewicz O. The neurochemical basis of the pharmacology of Parkinson's disease. Handb. Exp. Pharmacol. 88:1989;185-204.
14. Hu X.-T., Wang R.Y. Comparison of the effects of D1 and D2 dopamine receptor agonists on neurons in the rat caudate putamen: an electrophysiological study. J. Neurosci. 8:1988;4340-4348.
15. Hubble J.P., Killer W.C., Cutler N., Friedman J., Goetz C., Ranhosky A., Korts D., Elvin A. Pramipexole, a highly selective dopamine agonist, in patients with early Parkinson's disease: an ascending-dose trial. Clin. Neuropharmacol. 4:1995;338-347.
16. Kebabian J.W., Calne D.B. Multiple receptors for dopamine. Nature. 277:1979;93-96.
17. 3H]-hydroxy-N,N-di-n-propyl-2-aminotetralin. Proc. Natl. Acad. Sci. USA. 89:1992;8155-8159.
18. Meller E., Helmer-Matyjeck E., Bohmaker K., Adler C.H., Friedhoff A.J., Goldstein M. Receptor reserve at striatal dopamine autoreceptors: implications for selectivity of dopamine agonists. Eur. J. Pharmacol. 123:1986;311-314.
19. 4 receptor selective antagonist. J. Pharmacol. Exp. Ther. 279:1996;1392-1403.
20. 4 receptors. Eur. J. Pharmacol. 290:1995;29-36.
21. Mierau J., Schingnitz G. Biochemical and pharmacological studies on pramipexole, a potent and selective dopamine D2 receptor agonist. Eur. J. Pharmacol. 215:1992;161-170.
22. G. Paxinos, C. Watson, The Rat Brain in Stereotaxic Coordinates, 2nd ed., Academic Press, Sydney, Australia, 1986.
23. Piercey M.F., Camacho-Ochoa M., Smith M.W. Functional roles for dopamine-receptor subtypes. Clin. Neuropharmacol. 18(Suppl. 1):1995;S34-S42.
24. Piercey M.F., Hoffmann W.E., Vogelsang G.D. Electrophysiological evaluation of a partial agonist-antagonist of dopamine receptors. J. Pharmacol. Exp. Ther. 243:1987;391-396.
25. 3-preferring agonist: comparison to other dopamine agonists. Eur. J. Pharmacol. 312:1996;35-44.
26. Piercey M.F., Hyslop D.K., Hoffmann W.E. Excitation of type II caudate neurons by systemic administration of dopamine agonists. Brain Res. 706:1995;249-258.
27. Piercey M.F., Moon M.W., Sethy V.H., Schreur P.J.K.D., Smith M.W., Tang A.H., Von Voigtlander P.F. Pharmacology of U-91356A, a D2 receptor subtype dopamine agonist. Eur. J. Pharmacol. 317:1996;29-38.
28. Piercey M.F., Walker E.L., Feldpausch D.L., Camacho-Ochoa M. High affinity binding for pramipexole, a dopamine D3 receptor ligand, in rat striatum. Neurosci. Lett. 219:1996;138-140.
29. Rinne U.K. Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease: a 5-year follow-up. Neurology. 37:1987;826-828.
30. Rinne U.K. Lisuride, a dopamine agonist in the treatment of early Parkinson's disease. Neurology. 39:1989;336-339.
31. Rinne U.K. Dopamine agonists as primary treatment in Parkinson's disease. Adv. Neurol. 45:1986;519-523.
32. Setler P.E., Sarau H.M., Zircle C.L., Saunders H.L. The central effects of a novel dopamine agonist. Eur. J. Pharmacol. 50:1978;419-430.
33. Skirboll L.R., Bunney B.S. The effects of acute and chronic haloperidol treatment on spontaneously firing neurons in the caudate nucleus of the rat. Life Sci. 25:1979;1419-1434.
34. Skirboll L.R., Grace A.A., Bunney B.S. Dopamine auto- and postsynapticreceptors: electrophysiological evidence for differential sensitivity to dopamine agonists. Science. 206:1979;80-82.
35. 3) as a target for neuroleptics. Nature. 347:1990;146-151.
36. Surmeir D.J., Song W.J., Yan Z. Coordinated expression of dopamine receptors in neostriatal medium spiny neurons. J. Neurosci. 16:1996;6579-6591.
37. Vogelsang G.D., Piercey M.F. The supersensitivity of dopaminergic neurons to apomorphine in rats following chronic haloperidol. Eur. J. Pharmacol. 110:1985;267-269.
38. 3-receptor: a postsynaptic receptor inhibitory on rat locomotor activity. J. Neural Transm. 94:1993;11-19.
39. Xu M., Caine S.B., Cooper D.C., Gold L.H., Graybiel A.M., Hu X.T., Koelgzow T., Koob G.F., Moratella R., White F.J., Tonegawa S. Analyses of dopamine D3 and D1 receptor mutant mice. Neurosci. Abstr. 21:1995;363.
40. Yahr M.D. Parkinson's disease: new approaches to diagnosis and treatment. Neurol. Scand. 87(Suppl. 146):1993;22-25.